title: [News on infantile hemangioma therapy by beta-blocker].
abstract: Hemangiomas are benign tumors most commonly encountered in infancy and early childhood.           While most of them regress spontaneously, some require treatment due to a significant           proliferation, which may be complicated by ulceration, deformation aesthetic deformation           or worse impairment vital. Among the treatments used corticosteroids is the standard           treatment but its use in high doses expose to potential risks. In 2008, the discovery by           "chance" of the effectiveness of propranolol in the management of hemangioma           revolutionizes the first line treatment. Its mechanism of action is not yet well           understood and establishment of such treatment should be done by a hospital paediatrician           in the absence of any contraindications. This article proposes focus on effectiveness and           tolerance of β-blockers used as treatment of infantile hemangiomas.
authors.affiliation: Pharmacie à Usage Intérieur, AP-HM, Hôpital de la Conception, Marseille, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Delmotte
authors.forename: Christophe
authors.initials: C
authors.lastname: Curti
authors.forename: Marc
authors.initials: M
authors.lastname: Montana
authors.forename: Maxime
authors.initials: M
authors.lastname: Crozet
authors.forename: Patrice
authors.initials: P
authors.lastname: Vanelle
authors.forename: Sophie
authors.initials: S
authors.lastname: Gensollen
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D006391:Hemangioma / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007223:Infant; D011433:Propranolol / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D011433:Propranolol